Patents Issued in September 20, 2018
-
Publication number: 20180265568Abstract: The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.Type: ApplicationFiled: August 19, 2016Publication date: September 20, 2018Inventors: Karen Ann Delahay, Christopher John Arthur Finnis, Karl Michael Nicholls
-
Publication number: 20180265569Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: March 8, 2018Publication date: September 20, 2018Inventor: Karen Ann Delahay
-
Publication number: 20180265570Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: May 14, 2018Publication date: September 20, 2018Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20180265571Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.Type: ApplicationFiled: October 2, 2015Publication date: September 20, 2018Applicant: University of MassachusettsInventors: Miguel Sena ESTEVES, Sourav Roy CHOUDHURY
-
Publication number: 20180265572Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: January 10, 2018Publication date: September 20, 2018Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
-
Publication number: 20180265573Abstract: Provided herein are antibodies that cross-react with hemagglutinin from strains of influenza virus of the same subtype or different subtypes, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that cross-react with hemagglutinin from strains of influenza virus of the same subtype or different subtypes and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.Type: ApplicationFiled: January 22, 2018Publication date: September 20, 2018Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter Palese, Adolfo Garcia-Sastre, Gene Tan
-
Publication number: 20180265574Abstract: The present invention relates to compositions and methods for the treatment of infection caused by Streptococcus pneumonia. In particular, the invention provides human hyperimmune globulin and compositions thereof for preventing or treating pneumococcal infection. The invention provides methods of producing hyperimmune globulin containing high titers of opsonophagocytic anti-pneumococcal antibodies, compositions containing same, and methods of using the compositions for the prevention and treatment of pneumococcal infection. The invention further provides methods of preventing or treating pneumococcal infection (e.g., upper respiratory infections (e.g., bronchitis, otitis, sinusitis, etc.)) in immunocompromised subjects via administration of hyperimmune globulin compositions of the invention (e.g., containing a high titer of opsonophagocytic anti-pneumococcal antibodies) to immunocompromised subjects.Type: ApplicationFiled: March 15, 2017Publication date: September 20, 2018Inventors: James Mond, Adam S. Grossman
-
Publication number: 20180265575Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.Type: ApplicationFiled: March 16, 2018Publication date: September 20, 2018Inventors: Marc Mercken, Thomas Malia, Marianne Borgers, Kristof Van Kolen
-
Publication number: 20180265576Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.Type: ApplicationFiled: May 29, 2018Publication date: September 20, 2018Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
-
Publication number: 20180265577Abstract: Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including Alzheimer's disease, Progressive Supranuclear Palsy and Pick's disease.Type: ApplicationFiled: May 31, 2018Publication date: September 20, 2018Inventors: Mansuo Lu Hayashi, Jirong Lu, David Driver, Alberto Alvarado
-
Publication number: 20180265578Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.Type: ApplicationFiled: December 16, 2017Publication date: September 20, 2018Inventors: Edward Roland LaVallie, Lisa Anne Collins-Racie, Christopher John Corcoran, Lioudmila Gennadievna Tchistiakova, John Adam Nowak, Riyez Karim, Xiang-Yang Tan, Kimberly Ann Marquette, Geertruida Machteld Veldman
-
Publication number: 20180265579Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: May 24, 2018Publication date: September 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180265580Abstract: The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer.Type: ApplicationFiled: March 2, 2018Publication date: September 20, 2018Inventors: Julian Alexander Barden, Angus Gidley-Baird
-
Publication number: 20180265581Abstract: Certain embodiments of the disclosure relate to targeted binding agents that specifically bind to JAM-like protein and therein inhibit epithelial damage. Although it is not intended that embodiments of the disclosure be limited by any particular mechanism, it is believed that a possible mechanism by which this can be achieved may include, but are not limited to, either inhibition of binding of JAML to the CAR, inhibition of JAML induced CAR signaling, or increased clearance of JAML from the body of a subject, therein reducing the effective concentration of soluble JAML. In certain embodiment, the specific binding agent is a fully human antibody or chimera that specifically binds to human JAML, such as the JAML D1, and prevents JAML binding to CAR. Certain embodiments of the disclosure contemplate antibodies comprising human IgG type, e.g., IgG1, IgG2, IgG3, and IgG4.Type: ApplicationFiled: March 14, 2017Publication date: September 20, 2018Inventors: Charles A. Parkos, Dominique Weber
-
Publication number: 20180265582Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.Type: ApplicationFiled: January 20, 2017Publication date: September 20, 2018Applicant: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Publication number: 20180265583Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.Type: ApplicationFiled: March 23, 2018Publication date: September 20, 2018Inventors: Xue-Ping WANG, Philip M. ARLEN
-
Publication number: 20180265584Abstract: Methods and compounds for conferring site-specific or local immune privilege.Type: ApplicationFiled: March 15, 2018Publication date: September 20, 2018Inventors: Joanne L. Viney, Nathan Higginson-Scott, Micah Benson, Alan Crane
-
Publication number: 20180265585Abstract: Disclosed is a chimeric antigen receptor comprising an antigen binding domain; a hinge region; a transmembrane domain; a costimulatory domain; and a cytoplasmic signaling domainType: ApplicationFiled: August 5, 2016Publication date: September 20, 2018Inventor: Seogkyoung KONG
-
Publication number: 20180265586Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: January 10, 2018Publication date: September 20, 2018Applicant: ALECTOR LLCInventors: Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
-
Publication number: 20180265587Abstract: The present disclosure provides methods of modulating regulatory T-cell activity and function.Type: ApplicationFiled: April 6, 2016Publication date: September 20, 2018Inventor: Wayne A. MARASCO
-
Publication number: 20180265588Abstract: The present invention relates to a CD20 binding antibody which is capable of depleting B cells, and a BLyS binding antibody which is capable of antagonizing BLyS, as a combination for use in the treatment of an autoimmune disorder. The invention also relates to dosages, duration of treatment and time lapses between administration of the CD20 binding antibody which is capable of depleting B cells, and the BLyS binding antibody which is capable of antagonizing BLyS.Type: ApplicationFiled: September 21, 2016Publication date: September 20, 2018Inventor: Robert B. HENDERSON
-
Publication number: 20180265589Abstract: The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments.Type: ApplicationFiled: June 1, 2018Publication date: September 20, 2018Inventors: Jose A. Halperin, Michael Chorev
-
Publication number: 20180265590Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.Type: ApplicationFiled: May 17, 2018Publication date: September 20, 2018Inventors: Chi-Huey WONG, Chung-Yi WU, Che MA, Han-Chung WU
-
Publication number: 20180265591Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: January 10, 2018Publication date: September 20, 2018Inventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
-
Publication number: 20180265592Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: January 31, 2018Publication date: September 20, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Ayesha Sitlani, Carl P. Sparrow, Shilpa Pandit, Jon H. Condra, Holly A. Hammond
-
Publication number: 20180265593Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: ApplicationFiled: June 4, 2018Publication date: September 20, 2018Applicant: Juno Therapeutics, Inc.Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
-
Publication number: 20180265594Abstract: The present invention concerns anti-surrogate light chain antibodies and their uses. In particular, the present invention concerns anti-VpreB1 antibodies and their uses.Type: ApplicationFiled: January 27, 2016Publication date: September 20, 2018Inventor: Lawrence HOROWITZ
-
Publication number: 20180265595Abstract: Provided are monoclonal antibodies that detect CD19 CAR-modified immune cells and CAR-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of CAR-modified immune cells.Type: ApplicationFiled: March 5, 2018Publication date: September 20, 2018Inventors: Laurence JN COOPER, Bipulendu JENA, Sourindra MAITI, Harjeet SINGH, David RUSHWORTH
-
Publication number: 20180265596Abstract: The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an AD-ME-modulating moiety, and their uses.Type: ApplicationFiled: September 30, 2016Publication date: September 20, 2018Inventors: Bruce A. Keyt, Leonard George Presta, Ramesh Baliga
-
Publication number: 20180265597Abstract: An object of the invention is to provide a material comprising ultrafine cellulose fibers, having good dispersibility of fine particles in an aqueous medium containing ultrafine cellulose fibers. According to the invention, there is provided a material comprising ultrafine cellulose fibers, wherein the content of the ultrafine cellulose fibers is 80% by mass or more, and the haze value of a sample, which has been prepared by adding the material comprising ultrafine cellulose fibers to pure water to a solid concentration of 0.4% by mass, and stirring the mixture with a disperser under conditions of 1500 rpm and 5 minutes, is 20% or less.Type: ApplicationFiled: September 16, 2016Publication date: September 20, 2018Applicant: OJI HOLDINGS CORPORATIONInventors: Ikue HOMMA, Takayuki SHIMAOKA
-
Publication number: 20180265598Abstract: Methods for isolating cellulose nanocrystals (CNCs) from the plant Miscanthus Giganteus (MxG). Impressive yields are obtained through a combination of processing steps including base hydrolysis, bleaching and acid hydrolysis. MxG-CNCs are produced having high aspect ratios, are biorenewable and can be used for a wide range of applications such as nanofillers in composites. MxG-CNC-containing composites are also disclosed.Type: ApplicationFiled: May 21, 2018Publication date: September 20, 2018Inventors: Stuart Rowan, Mo Hunsen, Amanda Way
-
Publication number: 20180265599Abstract: An apparatus for continuously producing chemically-modified cellulose, the apparatus having a first mechanism for transporting a fine-powder cellulose fiber starting material and a hydrophobizing chemical substance, a specific extruder, a solvent tank connected to the extruder, and a dryer connected to the solvent tank, and a method for continuously producing chemically-modified cellulose, the method having a step of washing, in the solvent tank, chemically-modified cellulose having been produced out of the fine-powder cellulose fiber starting material and the hydrophobizing chemical substance in the extruder, and then drying the chemically-modified cellulose in the dryer, in order to remove any unreacted hydrophobizing chemical substance.Type: ApplicationFiled: September 30, 2016Publication date: September 20, 2018Inventors: Satoru NAKAMURA, Ryo ISHIGURO, Mariko YOSHIOKA
-
Publication number: 20180265600Abstract: A hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent. A process of preparing a hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules.Type: ApplicationFiled: December 17, 2015Publication date: September 20, 2018Inventors: Jean-Guy BOITEAU, Elin Saewen
-
Publication number: 20180265601Abstract: A rubber composition including guayule rubber and 15 to 90 phr silica. The rubber can be cis-1,4 polyisoprene and include 15 to 90 phr silica and contain less than 20% of the proteins associated with Hevea rubber and further include at least a trace of resins present in other natural rubbers. The rubber can be cis-1,4 polyisoprene and further include between at least a trace and 3% by weight of resins present in guayule rubber. The rubber composition can further be comprised of a synthetic rubber and include between about 40-100 phr of guayule rubber, and silica. The silica can be hydrophobated.Type: ApplicationFiled: January 12, 2016Publication date: September 20, 2018Inventor: Howard A. Colvin
-
Publication number: 20180265602Abstract: The present disclosure relates to a process for synthesizing multi- or dual-headed compositions having the formula R1MA[R2MA-]NR1 by employing a sterically hindered compound and an organometallic compound in the presence of a transition metal catalyst. The present disclosure further relates to use of the compositions, as well as the process to make the same, in olefin polymerization.Type: ApplicationFiled: September 28, 2016Publication date: September 20, 2018Inventors: Lixin Sun, David D. Devore
-
Publication number: 20180265603Abstract: A process may include contacting ethylene monomer with Ziegler-Natta catalyst to form polyethylene. The Ziegler-Natta catalyst may be formed by contacting an alkyl magnesium compound with an alcohol and a metal reagent to form a blend, and contacting the blend with a first agent to form a solution of reaction product “A”. The solution of reaction product “A” may be contacted with a second agent to form a solid reaction product “B”, and the solid reaction product “B” may be contacted with a third agent to form a solid reaction product “C”. The solid reaction product “C” may be contacted with a fourth agent to form a solid reaction product “D”, and the solid reaction product “D” may be contacted with a fifth agent to form a catalyst component.Type: ApplicationFiled: March 12, 2018Publication date: September 20, 2018Inventors: Lei Zhang, David Knoeppel
-
Publication number: 20180265604Abstract: A procatalyst for the polymerization of ethylene and optionally one or more alpha-olefins having the structure shown in formula (I) below. Formula (I) is provided. Also provided is a polymerization process using the inventive procatalyst.Type: ApplicationFiled: September 29, 2016Publication date: September 20, 2018Applicant: Dow Global Technologies LLCInventors: Ruth FIGUEROA, Johnathan DELORBE, Phillip P. FONTAINE, Jerzy KLOSIN, Ravi SHANKAR, Matthew YONKEY
-
Publication number: 20180265605Abstract: Provided are a novel metallocene-supported catalyst and a method of preparing a polyolefin using the same. The metallocene-supported catalyst according to the present disclosure may be used in the preparation of polyolefins, it may have excellent activity and excellent reactivity with comonomers, and it may prepare olefinic polymers having a high molecular weight and a low molecular weight.Type: ApplicationFiled: December 14, 2015Publication date: September 20, 2018Inventors: Eun Young SHIN, Heon Yong KWON, Se Young KIM, Hyun Jee KWON, Dae Sik HONG, Sung Min LEE, Ki Soo LEE
-
Publication number: 20180265606Abstract: Methods for treating solid metallocene compounds that are exposed to air are disclosed. These methods include a step of contacting the exposed solid metallocene compound with a purging gas stream containing an inert gas, and optionally, subjecting the exposed solid metallocene compound to a sub-atmospheric pressure.Type: ApplicationFiled: March 17, 2017Publication date: September 20, 2018Inventors: Qing Yang, Tony R. Crain, George R. Rajaendran
-
Publication number: 20180265607Abstract: Provided are polystyrene sulfonate analogs and methods of making polystyrene sulfonate analogs. The polystyrene sulfonate analogs may be formed by a ring opening metathesis polymerization (ROMP). The ROMP may provide analogs having a precise periodicity. The polystyrene sulfonate analogs may have a relatively low glass transition temperature.Type: ApplicationFiled: March 15, 2018Publication date: September 20, 2018Inventors: Justin G. Kennemur, William J. Neary
-
Publication number: 20180265608Abstract: The present invention provides a method for preparing a vinyl chloride-based polymer comprising performing suspension polymerization of vinyl chloride-based monomer, wherein an aromatic hydrocarbon-based compound is added when a pressure change is 0.5 to 1.5 kg/cm2 with respect to an equilibrium pressure at a polymerization temperature in a polymerization reactor after the vinyl chloride-based monomer is added to the polymerization reactor, wherein the aromatic hydrocarbon-based compound comprises a reactive functional group having an intracarbon double bond and a hydroxyl group; and a vinyl chloride-based polymer prepared by the method and having a high polymerization degree and excellent fusion processability.Type: ApplicationFiled: March 14, 2017Publication date: September 20, 2018Inventors: Joong Chul LIM, Hyun Kyou HA, Yang Jun JEON, Jin Hyuck JU, Min Jeong KANG
-
Publication number: 20180265609Abstract: The present invention provides a polymerizable liquid crystal composition including a specific polymerizable compound and a fluorosurfactant having a pentaerythritol skeleton or a dipentaerythritol skeleton in the molecule. In addition, an optically anisotropic body, a phase difference film, an antireflection film, and a liquid crystal display device, which are produced by using the polymerizable liquid crystal composition according to the present invention, are provided. The present invention is useful because three properties, that is, leveling properties of the surface of an optically anisotropic body, offset to a base material, and alignment properties of a liquid crystal can be improved at the same time in the case where the optically anisotropic body is produced by photopolymerizing the polymerizable liquid crystal composition.Type: ApplicationFiled: January 7, 2016Publication date: September 20, 2018Applicant: DIC CorporationInventors: Kouichi Endo, Mika Yamamoto, Kazuaki Hatsusaka
-
Publication number: 20180265610Abstract: A pneumatic tire produced by processing a rubber composition including a hydrogenated branched conjugated diene copolymer produced by copolymerizing a branched conjugated diene compound and a vinyl compound to form a branched conjugated diene copolymer and hydrogenating the branched conjugated diene copolymer. The branched conjugated diene compound is represented by formula (1), where R1 is an aliphatic hydrocarbon having 6 to 11 carbon atoms, the vinyl compound is represented by formula (3), where R4 is a hydrogen atom, an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, or an aromatic hydrocarbon group having 6 to 10 carbon atoms, copolymerization ratio of the branched conjugated diene compound is 1 to 99% by weight, copolymerization ratio of the vinyl compound is 99 to 1% by weight, the branched conjugated diene compound is myrcene and/or farnesene, and the vinyl compound is styrene.Type: ApplicationFiled: May 18, 2018Publication date: September 20, 2018Applicant: SUMITOMO RUBBER INDUSTRIES, LTD.Inventor: Kensuke Washizu
-
Publication number: 20180265611Abstract: Ethylene-based polymer is made by a process comprising polymerizing a reaction mixture comprising ethylene and at least one chain transfer agent system; wherein the polymerization takes place in the presence of at least one free-radical initiator; and wherein the polymerization takes place in a reactor configuration comprising at least one tubular reactor with at least three reaction zones; and wherein at least two reaction zones receive an ethylene feed; and wherein the degree of polymerization in the first reaction zone is less than, or equal to, (5/LCBf)*3150; and wherein the ethylene-based polymer formed by the process comprises the following properties: (A) LCBf?(4.7+0.5*log(I2)); and (B) I2 from 0.2 to 25 dg/min.Type: ApplicationFiled: September 20, 2016Publication date: September 20, 2018Inventors: Otto Berbee, Stefan Hinrichs, Nhi Dang, Juergen Siebdrat, Cornelis F.J. Den Doelder
-
Publication number: 20180265612Abstract: A solid catalyst component for olefin polymerization is produced by bringing a vinylsilane compound (d) into contact with a catalyst component, the catalyst component being a powdery solid component obtained by bringing a magnesium compound (a), a titanium halide compound (b), and an electron donor compound (c) into contact with each other, the electron donor compound (c) being one or more compounds that do not include a phthalic ester structure, and include one or more groups selected from an ester group, a carbonate group, and an ether group, the vinylsilane compound (d) being brought into contact with the catalyst component in a 0.1 to 15-fold molar quantity with respect to the molar quantity (on a titanium atom basis) of the titanium halide compound (b) included in the catalyst component.Type: ApplicationFiled: January 18, 2016Publication date: September 20, 2018Applicant: TOHO TITANIUM CO., LTD.Inventors: Hiroyuki Kono, Toshiya Uozumi, Shingo Yamada, Toshihiko Sugano
-
Publication number: 20180265613Abstract: Sequestrants of AGE precursors comprise amines separated by 2, 3 or 4 carbons. Sequestrants of AGE precursors can be used as pharmaceutical agents and in pharmaceutical compositions. The sequestrants of AGE precursors are particularly useful binding AGE precursors and dietary dicarbonyls in mammals in the gastrointestinal tract for the treatment of ailments such as diabetic nephropathy, chronic renal disease, atherosclerosis, stroke, cataracts, and Alzheimer's disease.Type: ApplicationFiled: December 14, 2017Publication date: September 20, 2018Inventors: Stephen Randall Holmes-Farley, Pradeep K. Dhal, Magnus Besev, Robert J. Miller, Andrew T. Papoulis
-
Publication number: 20180265614Abstract: The invention relates to novel linear, semi-crystalline fluoropolymers containing 0.5 to 25 mole percent of at least one vinyl ester monomer unit. At least 40 mole percent of the vinyl ester monomer units are present in the copolymer as single monomer units (not diads or triads or greater) between two fluoromonomer units. The invention also relates to a process for forming the fluoromonomers/vinyl ester copolymer. The fluoropolymer of the invention may be used in applications benefiting from a functional fluoropolymers including as a binder or coating in batteries, or for use in forming hydrophilic membranes and hollow fibers.Type: ApplicationFiled: May 23, 2018Publication date: September 20, 2018Inventor: Ramin Amin-Sanayei
-
Publication number: 20180265615Abstract: A method for producing a dispersant for solid particles, in particular a dispersant for mineral binder compositions. Ionizable monomers m1 and sidechain-carrying monomers m2 are polymerized to a copolymer, polymerization taking place as a living free radical polymerization.Type: ApplicationFiled: September 22, 2016Publication date: September 20, 2018Applicant: SIKA TECHNOLOGY AGInventors: Jürg WEIDMANN, Jörg ZIMMERMANN
-
Publication number: 20180265616Abstract: According to one embodiment, a pattern formation material is included in a polymer layer to be provided between a block copolymer layer and a substrate. The block copolymer layer includes a block copolymer including a plurality of blocks. The pattern formation material includes a pattern formation polymer. The pattern formation polymer consists of a main chain including an acrylic backbone, and a side chain. One of the plurality of blocks include a plurality of polymer components. The plurality of polymer components are of mutually-different types. A solubility parameter of the pattern formation material is between a maximum value and a minimum value of a solubility parameter of the polymer components.Type: ApplicationFiled: September 13, 2017Publication date: September 20, 2018Applicant: Toshiba Memory CorporationInventors: Koji ASAKAWA, Norikatsu Sasao, Tomoaki Sawabe, Naoko Kihara, Shinobu Sugimura
-
Publication number: 20180265617Abstract: The invention provides a method for producing an oxymethylene copolymer including a polymerization step for cationically polymerizing trioxane and a comonomer at a polymerization temperature of from 135 to 300° C. in the presence of at least one salt of a protonic acid having a molecular weight of 1,000 or less, and at least one polymerization initiator selected from the group consisting of protonic acids having a molecular weight of 1,000 or less, protonic acid anhydrides having a molecular weight of 1,000 or less, and protonic acid ester compounds having a molecular weight of 1,000 or less; wherein the total concentration of metal components contained in the trioxane and comonomer used in the polymerization step is 300 ppb by mass or less.Type: ApplicationFiled: December 1, 2015Publication date: September 20, 2018Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC.Inventors: Daigo NAKAYA, Toru TAKAHASHI, Satoshi MOCHIDA, Kensuke OSHIMA